HC Wainwright Predicts TC Biopharm FY2024 Earnings

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) – Equities research analysts at HC Wainwright issued their FY2024 earnings per share estimates for shares of TC Biopharm in a note issued to investors on Friday, December 6th. HC Wainwright analyst expects that the company will post earnings of ($0.01) per share for the year. HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. HC Wainwright also issued estimates for TC Biopharm’s FY2025 earnings at $0.00 EPS.

TC Biopharm Stock Up 1.5 %

TCBP stock opened at $0.65 on Monday. The firm has a 50-day simple moving average of $2.40 and a two-hundred day simple moving average of $5.68. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.12 and a quick ratio of 0.88. TC Biopharm has a one year low of $0.44 and a one year high of $72.00.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.